Physician profile
Charles Okoro
NPI 1427073980
$889.62
in general payments reported to CMS, 2019-2025
15 companies · $49.26 in 2025
The $49.26 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $124 · 2021: $36.84 · 2022: $77.84 · 2023: $168 · 2024: $164 · 2025: $49.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $120.38 | 2019 | |
| Abbott Laboratories | $120.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.48 | 2021-2024 | Jardiance |
| Biosense Webster, INC. | $87.10 | 2020 | |
| Janssen Pharmaceuticals, INC | $86.13 | 2023-2024 | Xarelto |
| Abiomed | $61.66 | 2024-2025 | Impella |
| Getinge USA Sales, LLC | $53.51 | 2019 | |
| Endologix LLC | $49.17 | 2023 | Ovation Ix Iliac Stent Graft |
| Kiniksa Pharmaceuticals International, Plc | $44.67 | 2024 | Arcalyst |
| Boston Scientific Corporation | $40.06 | 2023 | Watchman Flx |
| Ethicon US, LLC | $39.19 | 2024 | Surgicel Nu-Knit, Stratafix |
| Actelion Pharmaceuticals US, INC. | $39.11 | 2022 | |
| Chiesi USA, INC. | $24.07 | 2020 | |
| Kerecis Limited | $17.60 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| E.R. Squibb & Sons, L.L.C. | $13.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Okoro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.